You raised another point worth tying in here...the

You raised another point worth tying in here...their Novel stake. I think that rough 4 million profitability mark will take Elite a bit more time to reach than any hoped do to the API situation and Naltrexone taking a very very long time to launch. In essence, does Elite hang onto Novel and slowly but surely move towards profitability and take the Socius deal? I have also thought that hanging onto their Novel position may make a lot of sense from a future financial perspective.

As we all know Elite needs capital to pay for their R&D ART products and I feel that the sooner they get this capital the better. And then the debt issue dragging on the PPS like a boat anchor. While I appreciate making the company profitable through the various non abuse resistant products....the ART is still the hallmark of the company. I say sell the Novel stake....clear up the bond issue....and put the rest towards funding the ART products. Psychologically the company needs to strike while the iron is hot. Their flagship product received the patent in May. It would be fitting to be able to report substantial ongoing progress regarding this ART this coming May. Just my opinion....